Trial reportCanadian respiratory journal2025
Anxiety and Depression Among Astana Reinfected Patients at 1-, 3-, and 6-Month Follow-Up in the Post-COVID Center.
Trial report in Canadian respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the findings from an evaluation of 144 survivors who experienced post-COVID-19 complications or reinfection. The assessment was conducted at 1, 3, and 6 months following their discharge from an intensive post-COVID care center. The evaluation encompassed a comprehensive analysis of clinical life-critical indicators and mental health states. Based on lung CT scans, pneumonia was identified in 73% of the patients, categorized into four severity groups according to their health conditions: mild (26%), moderate (57%), severe (14%), and extremely severe (3%). Among the extremely severe cases, two patients succumbed to the illness. Self-reported fatigue during the acute phase was prevalent among 79% of participants, which increased to 91% at 1 month, decreased to 64% at 3 months, and further decreased to 56% at 6 months. The vital signs of patients, including systolic and diastolic blood pressure, oxygen saturation, body temperature, respiratory rate, and heart rate, gradually normalized over time. Anxiety and depression symptoms persisted in 17% and 21% of patients, respectively, up to the 6-month mark; even though during the acute phase, these figures were 15% and 13%. The limitations of this study include issues related to sample representation and the exclusion of hypertension data, which affect the overall balance of its findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.